TRAIL, caspases and maturation of normal and leukemic myeloid precursors

References

• Heissig B, Ohki Y, Sato Y, Rafii S, Werb Z, Hattori K. A role for niches in hematopoietic cell development. Hematology 2005; 10: 247–253
   PubMed Web of Science ®Google Scholar
• Park J R. Cytokine regulation of apoptosis in hematopoietic precursor cells. Curr Opin Hematol 1996; 3: 191–196
   PubMedGoogle Scholar
• Cantor A B, Orkin S H. Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene 2002; 21: 3368–3376
   PubMed Web of Science ®Google Scholar
• Perry C, Soreq H. Transcriptional regulation of erythropoiesis. Fine tuning of combinatorial multi-domain elements. Eur J Biochem 2002; 269: 3607–3618
   PubMedGoogle Scholar
• Skalnik D G. Transcriptional mechanisms regulating myeloid-specific genes. Gene 2002; 284: 1–21
   PubMed Web of Science ®Google Scholar
• Wiley S R, Schooley K, Smolak P J, Din W S, Huang C P, Nicholl J K, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673–682
   PubMed Web of Science ®Google Scholar
• De Maria R, Zeuner A, Eramo A, Domenichelli C, Bonci D, Grignani F, et al. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 1999; 401: 489–493
   PubMed Web of Science ®Google Scholar
• Zamai L, Secchiero P, Pierpaoli S, Bassini A, Papa S, Alnemri E S, et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 2000; 95: 3716–3724
   PubMed Web of Science ®Google Scholar
• Secchiero P, Melloni E, Heikinheimo M, Mannisto S, Di Pietro R, Iacone A, et al. TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood 2004; 103: 517–522
   PubMed Web of Science ®Google Scholar
• Mirandola P, Gobbi G, Ponti C, Sponzilli I, Cocco L, Vitale M. PKC{epsilon} controls the protection against TRAIL in erythroid progenitors. Blood Sep 15, 2005, [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Crist S A, Elzey B D, Ludwig A T, Griffith T S, Staack J B, Lentz S R, et al. Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets. Exp Hematol 2004; 32: 1073–1081
   PubMed Web of Science ®Google Scholar
• Melloni E, Secchiero P, Celeghini C, Campioni D, Grill V, Guidotti L, et al. Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development. J Cell Physiol 2005; 204: 975–982
   PubMed Web of Science ®Google Scholar
• Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C, et al. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood 2002; 100: 2421–2429
   PubMed Web of Science ®Google Scholar
• Secchiero P, Milani D, Gonelli A, Melloni E, Campioni D, Gibellini D, et al. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells. J Leukoc Biol 2003; 74: 223–232
   PubMed Web of Science ®Google Scholar
• Pitti R M, Marsters S A, Ruppert S, Donahue C J, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687–12690
   PubMed Web of Science ®Google Scholar
• Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003; 14: 337–348
   PubMed Web of Science ®Google Scholar
• Mariani S M, Krammer P H. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 1998; 28: 973–982
   PubMed Web of Science ®Google Scholar
• Liabakk N B, Sundan A, Torp S, Aukrust P, Froland S S, Espevik T. Development, characterization and use of monoclonal antibodies against sTRAIL: measurement of sTRAIL by ELISA. J Immunol Methods 2002; 259: 119–128
   PubMed Web of Science ®Google Scholar
• Gruss H J. Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Int J Clin Lab Res 1996; 26: 143–159
   PubMedGoogle Scholar
• Pan G, O'Rourke K, Chinnaiyan A M, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111–113
   PubMed Web of Science ®Google Scholar
• Hymowitz S G, Ultsch M H, Hurst A, Totpal K, Ashkenazi A, De Vos A M, et al. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000; 39: 633–640
   PubMed Web of Science ®Google Scholar
• Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004; 201: 331–340
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Pai R C, Fong S, Leung S, Lawrence D A, Marsters S A, , et al. Safety and anti tumor activity of recombinant soluble Apo2 ligand. J Clin Investig 1999; 104: 155–162
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller R E, Ariail K, Gliniak B, Griffith T S, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157–163
   PubMed Web of Science ®Google Scholar
• Bouralexis S, Findlay D M, Evdokiou A. Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 2005; 10: 35–51
   PubMed Web of Science ®Google Scholar
• Secchiero P, Vaccarezza M, Gonelli A, Zauli G. TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies. Curr Pharm Des 2004; 10: 3673–3681
   PubMed Web of Science ®Google Scholar
• Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E, et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 2002; 16: 67–73
   PubMed Web of Science ®Google Scholar
• Jones D T, Ganeshaguru K, Mitchell W A, Foroni L, Baker R J, Prentice H G, et al. Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand. Br J Haematol 2003; 121: 713–720
   PubMed Web of Science ®Google Scholar
• Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71–76
   PubMed Web of Science ®Google Scholar
• Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005; 11: 77–84
   PubMed Web of Science ®Google Scholar
• Zang D Y, Goodwin R G, Loken M R, Bryant E, Deeg H J. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 2001; 98: 3058–3065
   PubMed Web of Science ®Google Scholar
• Uno K, Inukai T, Kayagaki N, Goi K, Sato H, Nemoto A, et al. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood 2003; 101: 3658–3667
   PubMed Web of Science ®Google Scholar
• Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 1999; 13: 1817–1824
   PubMed Web of Science ®Google Scholar
• Gazitt Y, Shaughnessy P, Montgomery W. Apoptosis-induced by TRAIL and TNF-alpha in human multiple myeloma cells is not blocked by BCL-2. Cytokine 1999; 11: 1010–1019
   PubMed Web of Science ®Google Scholar
• Liu Q, El-Deiry W S, Gazitt Y. Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines. Exp Hematol 2001; 29: 962–970
   PubMed Web of Science ®Google Scholar
• Spencer A, Yeh S L, Koutrevelis K, Baulch-Brown C. TRAIL-induced apoptosis of authentic myeloma cells does not correlate with the procaspase-8/cFLIP ratio. Blood 2002; 100: 3049
   PubMed Web of Science ®Google Scholar
• Fandy T E, Shankar S, Ross D D, Sausville E, Srivastava R K. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005; 7: 646–657
   PubMed Web of Science ®Google Scholar
• Sheridan J P, Marsters S A, Pitti R M, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818–821
   PubMed Web of Science ®Google Scholar
• Ashkenazi A. Targeting death and decoy receptors of the tumour necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420–430
   PubMed Web of Science ®Google Scholar
• Kimberley F C, Screaton G R. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004; 14: 359–372
   PubMed Web of Science ®Google Scholar
• Chaudhary P M, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD- dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997; 7: 821–830
   PubMed Web of Science ®Google Scholar
• MacFarlane M, Ahmad M, Srinivasula S M, Fernandes-Alnemri T, Cohen G M, Alnemri E S. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272: 25417–25420
   PubMed Web of Science ®Google Scholar
• Screaton G R, Mongkolsapaya J, Xu X N, Cowper A E, McMichael A J, Bell J I. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997; 7: 693–696
   PubMed Web of Science ®Google Scholar
• Walczak H, Degli-Esposti M A, Johnson R S, Smolak P J, Waugh J Y, Boiani N, et al. TRAILR2: a novel apoptosis-mediating receptor for TRAIL. Embo J 1997; 16: 5386–5397
   PubMed Web of Science ®Google Scholar
• Wu G S, Burns T F, McDonald E R, Jiang W, Meng R, Krantz I D, et al. KILLER/DR5 is a DNA damage-inducible p53 regulated death receptor gene. Nat Genet 1997; 17: 141–143
   PubMed Web of Science ®Google Scholar
• Degli-Esposti M A, Smolak P J, Walczak H, Waugh J, Huang C P, DuBose R F, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186: 1165–1170
   PubMed Web of Science ®Google Scholar
• Pan G, Ni J, Yu G, Wei Y F, Dixit V M. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling. FEBS Lett 1998; 424: 41–45
   PubMed Web of Science ®Google Scholar
• Marsters S A, Sheridan J P, Pitti R M, Huang A, Skubatch M, Baldwin D, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997; 7: 1003–1006
   PubMed Web of Science ®Google Scholar
• Degli-Esposti M A, Dougall W C, Smolak P J, Waugh J Y, Smith C A, Goodwin R G. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7: 813–820
   PubMed Web of Science ®Google Scholar
• Sheikh M S, Fornace A J, Jr. Death and decoy receptors and p53-mediated apoptosis. Leukemia 2000; 14: 1509–1513
   PubMed Web of Science ®Google Scholar
• Ozoren N, El-Deiry W S. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 2003; 13: 135–147
   PubMed Web of Science ®Google Scholar
• Sheikh M S, Huang Y, Fernandez-Salas E A, El-Deiry W S, Friess H, Amundson S, et al. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene 1999; 18: 4153–4159
   PubMed Web of Science ®Google Scholar
• Meng R D, McDonald E R, Sheikh M S, Fornace A J, Jr, El-Deiry W S. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther 2000; 1: 130–144
   PubMed Web of Science ®Google Scholar
• Ruiz de Almodovar C, Ruiz-Ruiz C, Rodriguez A, Ortiz-Ferron G, Redondo J M, Lopez-Rivas A. TRAIL decoy receptor TRAIL-R3 is upregulated by p53 in breast tumor cells through a mechanism involving an intronic p53 binding site. J Biol Chem 2004; 279: 4093–4101
   PubMed Web of Science ®Google Scholar
• Emery J G, McDonnell P, Burke M B, Deen K C, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363–14367
   PubMed Web of Science ®Google Scholar
• Truneh A, Sharma S, Silverman C, Khandekar S, Reddy M P, Deen K C, et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 2000; 275: 23319–23325
   PubMed Web of Science ®Google Scholar
• Holen I, Croucher P I, Hamdy F C, Eaton C L. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002; 62: 1619–1623
   PubMed Web of Science ®Google Scholar
• Miyashita T, Kawakami A, Nakashima T, Yamasaki S, Tamai M, Tanaka F, et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol 2004; 137: 430–436
   PubMed Web of Science ®Google Scholar
• Kim K, Fisher M J, Xu S Q, el-Deiry W S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6: 335–346
   PubMed Web of Science ®Google Scholar
• Pan G, Ni J, Wei Y F, Yu G, Gentz R, Dixit V M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815–818
   PubMed Web of Science ®Google Scholar
• Mongkolsapaya J, Cowper A E, Xu X N, Morris G, McMichael A J, Bell J I, et al. Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. J Immunol 1998; 160: 3–6
   Web of Science ®Google Scholar
• Wuchter C, Krappmann D, Cai Z, Ruppert V, Scheidereit C, Dorken B, et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kB activity. Leukemia 2001; 15: 921–928
   PubMed Web of Science ®Google Scholar
• Lincz L F, Yeh T X, Spencer A. TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 2001; 15: 1650–1657
   PubMed Web of Science ®Google Scholar
• Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003; 107: 2250–2256
   PubMed Web of Science ®Google Scholar
• Secchiero P, Zerbinati C, Rimondi E, Corallini F, Milani D, Grill V, et al. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 2004; 61: 1965–1974
   PubMed Web of Science ®Google Scholar
• Mirandola P, Ponti C, Gobbi G, Sponzilli I, Vaccarezza M, Cocco L, et al. Activated human NK and CD8 + T cells express both TNF-related apoptosis inducing ligand (TRAIL) and TRAIL receptors, but are resistant to TRAIL-mediated cytotoxicity. Blood 2004; 104: 2418–2424
   PubMed Web of Science ®Google Scholar
• Secchiero P, Tiribelli M, Barbarotto E, Celeghini C, Michelutti A, Masolini P, et al. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. J Cell Physiol 2005; 205: 246–252
   PubMed Web of Science ®Google Scholar
• Griffith T S, Chin W A, Jackson G C, Lynch D H, Kubin M Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161: 2833–2840
   PubMed Web of Science ®Google Scholar
• Zhang X D, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999; 59: 2747–2753
   PubMed Web of Science ®Google Scholar
• Chinnaiyan A M, O'Rourke K, Tewari M, Dixit V M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505–512
   PubMed Web of Science ®Google Scholar
• Boldin M P, Mett I L, Varfolomeev E E, Chumakov I, Shemer-Avni Y, Camonis J H, et al. Self-association of the “death domains” of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem 1995; 270: 387–391
   PubMed Web of Science ®Google Scholar
• Kischkel F C, Lawrence D A, Tinel A, LeBlanc H, Virmani A, Schow P, et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 2001; 276: 46639–46646
   PubMed Web of Science ®Google Scholar
• Muhlenbeck F, Haas E, Schwenzer R, Schubert G, Grell M, Smith C, et al. TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways. J Biol Chem 1998; 273: 33091–33098
   PubMed Web of Science ®Google Scholar
• Herr I, Wilhelm D, Meyer E, Jeremias I, Angel P, Debatin K M. JNK/SAPK activity contributes to TRAIL-induced apoptosis. Cell Death Differ 1999; 6: 130–135
   PubMed Web of Science ®Google Scholar
• Wachter T, Sprick M, Hausmann D, Kerstan A, McPherson K, Stassi G, et al. cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes. J Biol Chem 2004; 279: 52824–52834
   PubMed Web of Science ®Google Scholar
• Ricci M S, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker D T, et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004; 24: 8541–8555
   PubMed Web of Science ®Google Scholar
• Sharp D A, Lawrence D A, Ashkenazi A. Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 2005; 280: 19401–19409
   PubMedGoogle Scholar
• Sprick M R, Walczak H. The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim Biophys Acta 2004; 1644: 125–132
   PubMed Web of Science ®Google Scholar
• Harper N, Farrow S N, Kaptein A, Cohen G M, MacFarlane M. Modulation of tumor necrosis factor apoptosis-inducing ligand-induced NF-kappaB activation by inhibition of apical caspases. J Biol Chem 2001; 276: 34743–34752
   PubMed Web of Science ®Google Scholar
• Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 2003; 92: 732–740
   PubMed Web of Science ®Google Scholar
• Hu W H, Johnson H, Shu H B. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem 1999; 274: 30603–30610
   PubMed Web of Science ®Google Scholar
• Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F, et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 2005; 166: 557–563
   PubMed Web of Science ®Google Scholar
• Schmidt U, van den Akker E, Parren-van Amelsvoort M, Litos G, De Bruijn M, Gutierrez L, et al. Btk is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid cells. J Exp Med 2004; 199: 785–795
   PubMed Web of Science ®Google Scholar
• Silvestris F, Cafforio P, Tucci M, Dammacco F. Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood 2002; 99: 1305–1313
   PubMed Web of Science ®Google Scholar
• Miyazaki R, Ogata H, Kobayashi Y. Requirement of thrombopoietin-induced activation of ERK for megakaryocyte differentiation and of p38 for erythroid differentiation. Ann Hematol 2001; 80: 284–291
   PubMed Web of Science ®Google Scholar
• Choi J W. Relationships between tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and hematopoietic activity in healthy adults. Ann Hematol 2005; 84: 728–733
   PubMed Web of Science ®Google Scholar
• Kawamoto H, Minato N. Myeloid cells. Int J Bioch Cell Biol 2004; 36: 1374–1379
   PubMed Web of Science ®Google Scholar
• Ferrari S, Tagliafico E, Ceccherelli G, Selleri L, Calabretta B, Donelli A, et al. Expression of the myeloperoxidase gene in acute and chronic myeloid leukemias: relationship to the expression of cell cycle-related genes. Leukemia 1989; 3: 423–430
   PubMed Web of Science ®Google Scholar
• Schwaller J, Pabst T, Koeffler H P, Niklaus G, Loetscher P, Fey M F, et al. Expression and regulation of G1 cell-cycle inhibitors (p16INK4A, p15INK4B, p18INK4C, p19INK4D) in human acute myeloid leukemia and normal myeloid cells. Leukemia 1997; 11: 54–63
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Drexler H G. Classification of acute myeloid leukemias: a comparison of FAB and immunophenotyping. Leukemia 1987; 1: 697–705
   PubMed Web of Science ®Google Scholar
• Ferrari S, Grande A, Manfredini R, Tagliafico E, Zucchini P, Torelli G, et al. Expression of interleukins 1, 3, 6, stem cell factor and their receptors in acute leukemia blast cells and in normal peripheral lymphocytes and monocytes. Eur J Haematol 1993; 50: 141–148
   PubMed Web of Science ®Google Scholar
• Ferrari S, Grande A, Zucchini P, Manfredini R, Tagliafico E, Rossi E, et al. Overexpression of c-kit in a leukemic cell population carrying a trisomy 4 and its relationship with the proliferative capacity. Leuk Lymphoma 1993; 9: 495–501
   PubMed Web of Science ®Google Scholar
• Olsson I, Bergh G, Ehinger M, Gullberg U. Cell differentiation in acute myeloid leukemia. Eur J Haematol 1996; 57: 1–16
   PubMed Web of Science ®Google Scholar
• Irvine A E, Berney J J, Francis G E. Dissociation of the proliferation and differentiation stimuli of granulocyte colony-stimulating factor (G-CSF). Leukemia 1990; 4: 203–209
   PubMed Web of Science ®Google Scholar
• Castaigne S, Chomienne C, Daniel M T, Ballerini P, Berger R, Fenaux P, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: clinical results. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Chomienne C, Fenaux P, Degos L. Retinoid differentiation therapy in promyelocytic leukemia. FASEB J 1996; 10: 1025–1030
   PubMed Web of Science ®Google Scholar
• Collins S J. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 1987; 70: 1233–1244
   PubMed Web of Science ®Google Scholar
• Sokoloski J A, Hodnick W F, Mayne S T, Cinquina C, Kim C S, Sartorelli A C. Induction of the differentiation of HL-60 promyelocytic leukemia cells by vitamin E and other antioxidants in combination with low levels of vitamin D3: possible relationship to NF-kappa B. Leukemia 1997; 11: 1546–1553
   PubMed Web of Science ®Google Scholar
• Medupalli A, Li Z, Hromchak R, Bloch A. NF-kappaB (p65/RelA) as a regulator of TNF alpha-mediated ML-1 cell differentiation. Leukemia 2001; 15: 808–813
   PubMed Web of Science ®Google Scholar
• Richter G, Hayden-Ledbetter M, Irgang M, Ledbetter J A, Westermann J, Korner I, et al. Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34(+) progenitor cells during differentiation into antigen presenting cells. J Biol Chem 2001; 276: 45686–45693
   PubMed Web of Science ®Google Scholar
• Berry D M, Clark C S, Meckling-Gill K A. 1α,25-dihydroxyvitamin D3 stimulates phosphorylation of IκBα and synergizes with TPA to induce nuclear translocation of NFκB during monocytic differentiation of NB4 leukemia cells. Exp Cell Res 2002; 272: 176–184
   PubMed Web of Science ®Google Scholar
• Wang J, Lenardo M J. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J Cell Sci 2000; 113: 753–757
   PubMed Web of Science ®Google Scholar
• Zermati Y, Garrido C, Amsellem S, Fishelson S, Bouscary D, Valensi F, et al. Caspase activation is required for terminal erythroid differentiation. J Exp Med 2001; 193: 247–254
   PubMed Web of Science ®Google Scholar
• Alam A, Cohen L Y, Aouad S, Sekaly R P. Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. J Exp Med 1999; 190: 1879–1890
   PubMed Web of Science ®Google Scholar
• Kennedy N, Kataoka T, Tschopp J, Budd R C. Caspase activation is required for T cell proliferation. J Exp Med 1999; 190: 1891–1895
   PubMed Web of Science ®Google Scholar
• Chun H J, Zheng L, Ahmad M, Wang J, Speirs C K, Siegel R M, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002; 419: 395–399
   PubMed Web of Science ®Google Scholar
• Trauzold A, Wermann H, Arlt A, Schutze S, Schafer H, Oestern S, et al. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001; 20: 4258–4269
   PubMed Web of Science ®Google Scholar
• Chaudhary P M, Eby M T, Jasmin A, Kumar A, Liu L, Hood L. Activation of the NF-kB pathway by caspase 8 and its homologs. Oncogene 2000; 19: 4451–4460
   PubMed Web of Science ®Google Scholar
• Hu W H, Johnson H, Shu H B. Activation of NF-kB by FADD, casper, and caspase 8. J Biol Chem 2000; 275: 10838–10844
   PubMed Web of Science ®Google Scholar
• Rathore N, Matta H, Chaudhary P M. An evolutionary conserved pathway of nuclear factor-kappaB activation involving caspase-mediated cleavage and N-end rule pathway-mediated degradation of IkappaBalpha. J Biol Chem 2004; 279: 39358–39365
   PubMed Web of Science ®Google Scholar